Godfreybagge1734

016, 95% CI 1.3 - 18.5) and work hours > 60 hour/week (OR=2.6 p= 0.019, 95% CI 1.16 - 5.6). Practitioners in group practice were 57% less likely to burnout (OR=0.43 p=0.029 95% CI 0.20-0.92), as were those who spend > 20% of their time in personally satisfying work (OR=0.32 p=0.005 95% CI 0.15-0.71). CONCLUSION In what we believe to be one of the largest studies regarding burnout among rheumatology practitioners, we found a substantial prevalence of burnout, with 51% of all respondents meeting criteria in at least one domain defined by the MBI™ and 54% of physicians meeting this same criterion.OBJECTIVE To examine the value of optical spectral transmission (OST) in detecting joint inflammation in patients with rheumatoid arthritis (RA) and to evaluate whether OST correlates with certain patient characteristics. METHODS OST measurements were performed in the metacarpophalangeal, proximal intraphalangeal and wrist joints of 168 RA patients and 114 controls. OST difference between the two groups was statistically examined and subsequently controlled for the effect of possible confounding factors. Diagnostic OST performance was tested by Receiver Operating Characteristics. Moreover, associations of OST with clinical and serological activity markers (patient group), joint ultrasound (US) (patient subgroup) and various anthropometric and epidemiologic parameters (patient and control group) were evaluated by Spearmann's test and a generalized linear statistical adjustment model. RESULTS OST was significantly higher in the RA group than in the control group, even after adjustment for confounding factors [1.89; 95%CI(0.709-3.070), padj=0.002)]. Taking US as a reference, Area Under the Curve (AUC) for all 1,251 joints simultaneously was 0.67 (95%CI=0.631- 0.709). In the patient group, correlation and adjustment analyses showed associations of OST with various disease activity markers [DAS28 (rho=0.313), swollen joint counts (rho=0.361), CRP (rho=0.389); all, padj=0.001)], age (rho=0.276, p less then 0.001) and osteoarthritis (p=0.022). Moreover, OST associated with a power-Doppler- (rho=0.442; p=0.001) and a grey-scale- US-Score (rho=0.591; p less then 0.001). In both groups males had significantly higher OST values than females and OST associated moderately-weakly with Body-Mass-Index (rhopatients=0.316, rhocontrols=0.24) (all; p less then 0.001). CONCLUSION RA patients showed higher OST values in comparison to controls. Moreover, OST associated with clinical, US and laboratory disease activity markers.OBJECTIVE To examine the role of disease activity on organ damage over 5 years in patients with active systemic lupus erythematosus (SLE) despite standard of care. METHODS This analysis of the University of Toronto Lupus Clinic cohort assessed organ damage (measured by Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) in patients with active SLE (SLE Disease Activity Index- 2000 [SLEDAI-2K] ≥6), using Cox proportional time-independent hazard models. Subgroup analyses were conducted in patients with SLEDAI-2K 6 or 7, 8 or 9, and ≥10 at baseline, and in the overall study population by steroid dose at study entry (0 was generally consistent across all SLEDAI-2K subgroups. Multivariable analyses identified age at study start (hazard ratio [HR] 1.03, p less then 0.0001), steroid dose (HR 2.03, p less then 0.0001), immunosuppressants (HR 1.44, p=0.021), and SLEDAI-2K (subgroup analyses HR 1.64─2.03, p=0.0017─ less then 0.0001) as the greatest risk factors for SDI progression, while a study start date after the year 2000 had a protective effect on SDI progression compared with a start date prior to the year 2000 (HR 0.65, p=0.0004). CONCLUSION Patients within the higher SLEDAI-2K subgroups at study entry, or receiving high doses of steroids, were more likely to have organ damage progression.OBJECTIVE A meta-analysis of published studies was performed to determine whether the efficacy of antiseizure drugs in adults with primary generalized tonic-clonic seizures (PGTCS) is comparable with that in the pediatric population (2-12 years of age). METHODS Electronic searches were conducted in EMBASE, Medline, and the Cochrane Central Register of Controlled Trials for clinical trials of PGTCS in adults and children 2-12 years of age. Neurologists used standardized search and study evaluations to select eligible trials. Median percent reduction in seizure frequency from baseline and ≥50% responder rates were used to compare drug efficacy in adults and children. RESULTS Among 7 adjunctive-therapy PGTCS trials in adults and children (2-12 years of age) that met evaluation criteria, effect sizes were consistent between adults and children for lamotrigine and topiramate. The baseline-subtracted median percent seizure reduction in seizure frequency ranged from 50.0% to 79.7% in children and 57.0% to 64.0% in adults. The ≥50% responder rate was similar between children and adults in a topiramate study (50% in children compared with 58% in adults). CONCLUSIONS This meta-analysis supports the use of drug response from antiseizure drug clinical trials for PGTCS in adults to predict comparable treatment response in children 2-12 years of age with PGTCS. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.OBJECTIVE To determine whether, for patients with depression and Parkinson disease (PD), telephone-based cognitive-behavioral treatment (T-CBT) alleviates depressive symptoms significantly more than treatment as usual (TAU), we conducted a randomized controlled trial to evaluate the efficacy of a 10-session T-CBT intervention for depression in PD, compared to TAU. PTX inhibitor mw METHODS Seventy-two people with PD (PWP) were randomized to T-CBT + TAU or TAU only. T-CBT tailored to PWPs' unique needs was provided weekly for 3 months, then monthly during 6-month follow-up. CBT targeted negative thoughts (e.g., "I have no control"; "I am helpless") and behaviors (e.g., social withdrawal, excessive worry). It also trained care partners to help PWP practice healthy habits. Blind raters assessed outcomes at baseline, midtreatment, treatment end, and 1 and 6 months post-treatment. Analyses were intent to treat. RESULTS T-CBT outperformed TAU on all depression, anxiety, and quality of life measures. The primary outcome (Hamilton Depression Rating Scale score) improved significantly in T-CBT compared to TAU by treatment end.